Millennium Management’s Sonnet BioTherapeutics SONN Stock Holding History

Millennium Management’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-16	Closed	-$11K	–	7461
2022 Q2	$11K	Sell	16 -142	-90%	-$102K	﹤0.01%	6650
2022 Q1	$147K	Buy	+158	New	+$134K	﹤0.01%	5979
2015 Q4	–	Hold	0	–	-$227K	–	3742
2015 Q3	–	Hold	0	–	–	–	3059
2015 Q2	–	Hold	0	–	–	–	2637
2015 Q1	–	Hold	0	–	–	–	2717
2014 Q4	–	Hold	0	–	–	–	3185
2014 Q3	–	Hold	0	–	–	–	2795
2014 Q2	–	Hold	0	–	–	–	2506
2014 Q1	–	Hold	0	–	–	–	2333
2013 Q4	–	Hold	0	–	–	–	2161
2013 Q3	–	Hold	0	–	–	–	2065
2013 Q2	–	Hold	0	–	–	–	2189

Other funds holding SONN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Millennium Management's SONN Position: Q3 2022 in Review

Millennium Management sold out of Sonnet BioTherapeutics (SONN) in Q3 2022, closing a stake of 16 shares — an estimated $11K sold.

Millennium Management first reported a position in SONN in Q1 2022 and held it in 2 quarters. The position peaked at $147K in Q1 2022. 10 funds tracked by Wall St. Rank hold SONN as of Q3 2022.

Millennium Management reported no remaining Sonnet BioTherapeutics position as of Q3 2022 after selling out during the quarter.
Millennium Management sold 16 Sonnet BioTherapeutics shares in Q3 2022, an estimated $11K.
Millennium Management first reported a position in Sonnet BioTherapeutics in Q1 2022 and held it in 2 quarters.
Millennium Management's Sonnet BioTherapeutics position peaked at $147K in Q1 2022.
10 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q3 2022.

Based on Millennium Management's 13F filing for Q3 2022, filed 14 Nov 2022.